In vitro antimicrobial effect of cefazolin and cefotaxime combined with minocycline against Vibrio cholerae non-O1 non-O139

Bo An Su, Hung Jen Tang, Yin Yi Wang, Yung Ching Liu, Wen Chien Ko, Cheng Yi Liu, Yin Ching Chuang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The most common clinical manifestation of Vibrio cholerae non-O1 non-O139 is gastroenteritis. This vibrion may also cause bacteremia, soft tissue infection, and other extraintestinal invasive disease, especially in immunocompromised patients. This study evaluated the current status of antimicrobial resistance in clinical isolates of V. cholerae non-O1 non-O139 in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Minimal inhibitory concentrations (MICs) of 9 antimicrobial agents were determined by the agar dilution method. All of the isolates were susceptible to minocycline (MIC at which 90% of the isolates were inhibited [MIC90], 0.12 μg/mL), cefotaxime (MIC90, 0.06 μg/mL), lomefloxacin (MIC90, 0.12 μg/mL), levofloxacin (MIC90, 0.03 μg/mL), ciprofloxacin (MIC90, 0.03 μg/mL), moxifloxacin (MIC90, 0.06 μg/mL), sparfloxacin (MIC90, 0.06 μg/mL), gatifloxacin (MIC90, 0.03 μg/mL), and cefazolin (MIC90, 8 μg/mL). We conducted time-kill studies to evaluate the inhibitory activities of either cefazolin or minocycline alone or in combination against V. cholerae non-O1 non-O139 (Vc2). We also evaluated the inhibitory activity of cefazolin or cefotaxime combined with minocycline. The individual MICs of cefazolin, cefotaxime, and minocycline were 4 μg/mL, 0.0075 μg/mL, and 0.12 μg/mL, respectively, when approximately 5 × 105 colony-forming units/mL of V. cholerae non-O1 non-O139 was incubated. Bacterial growth was inhibited initially but resumed later when cefazolin, cefotaxime, or minocycline was used alone. When cefazoline or cefotaxime was combined with minocycline, V. cholerae non-O1 non-O139 was inhibited over 48 h and no regrowth was noted. We conclude that the combination of cefazolin or cefotaxime with minocycline has a synergistic inhibitory effect on V. cholerae non-O1 non-0139 in vitro.

Original languageEnglish
Pages (from-to)425-429
Number of pages5
JournalJournal of Microbiology, Immunology and Infection
Volume38
Issue number6
Publication statusPublished - Dec 2005
Externally publishedYes

Fingerprint

Vibrio cholerae non-O1
Cefazolin
Minocycline
Cefotaxime
Taiwan
Levofloxacin
Soft Tissue Infections
Gastroenteritis
Immunocompromised Host
Ciprofloxacin
Bacteremia
Anti-Infective Agents
In Vitro Techniques
Agar
Stem Cells

Keywords

  • Combined antibiotics
  • Microbial sensitivity tests
  • Vibrio cholerae non-O1
  • Vibrio infections

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Immunology and Microbiology(all)

Cite this

In vitro antimicrobial effect of cefazolin and cefotaxime combined with minocycline against Vibrio cholerae non-O1 non-O139. / Su, Bo An; Tang, Hung Jen; Wang, Yin Yi; Liu, Yung Ching; Ko, Wen Chien; Liu, Cheng Yi; Chuang, Yin Ching.

In: Journal of Microbiology, Immunology and Infection, Vol. 38, No. 6, 12.2005, p. 425-429.

Research output: Contribution to journalArticle

Su, Bo An ; Tang, Hung Jen ; Wang, Yin Yi ; Liu, Yung Ching ; Ko, Wen Chien ; Liu, Cheng Yi ; Chuang, Yin Ching. / In vitro antimicrobial effect of cefazolin and cefotaxime combined with minocycline against Vibrio cholerae non-O1 non-O139. In: Journal of Microbiology, Immunology and Infection. 2005 ; Vol. 38, No. 6. pp. 425-429.
@article{bbe90c062bbe48d2911f53bf1e8080a5,
title = "In vitro antimicrobial effect of cefazolin and cefotaxime combined with minocycline against Vibrio cholerae non-O1 non-O139",
abstract = "The most common clinical manifestation of Vibrio cholerae non-O1 non-O139 is gastroenteritis. This vibrion may also cause bacteremia, soft tissue infection, and other extraintestinal invasive disease, especially in immunocompromised patients. This study evaluated the current status of antimicrobial resistance in clinical isolates of V. cholerae non-O1 non-O139 in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Minimal inhibitory concentrations (MICs) of 9 antimicrobial agents were determined by the agar dilution method. All of the isolates were susceptible to minocycline (MIC at which 90{\%} of the isolates were inhibited [MIC90], 0.12 μg/mL), cefotaxime (MIC90, 0.06 μg/mL), lomefloxacin (MIC90, 0.12 μg/mL), levofloxacin (MIC90, 0.03 μg/mL), ciprofloxacin (MIC90, 0.03 μg/mL), moxifloxacin (MIC90, 0.06 μg/mL), sparfloxacin (MIC90, 0.06 μg/mL), gatifloxacin (MIC90, 0.03 μg/mL), and cefazolin (MIC90, 8 μg/mL). We conducted time-kill studies to evaluate the inhibitory activities of either cefazolin or minocycline alone or in combination against V. cholerae non-O1 non-O139 (Vc2). We also evaluated the inhibitory activity of cefazolin or cefotaxime combined with minocycline. The individual MICs of cefazolin, cefotaxime, and minocycline were 4 μg/mL, 0.0075 μg/mL, and 0.12 μg/mL, respectively, when approximately 5 × 105 colony-forming units/mL of V. cholerae non-O1 non-O139 was incubated. Bacterial growth was inhibited initially but resumed later when cefazolin, cefotaxime, or minocycline was used alone. When cefazoline or cefotaxime was combined with minocycline, V. cholerae non-O1 non-O139 was inhibited over 48 h and no regrowth was noted. We conclude that the combination of cefazolin or cefotaxime with minocycline has a synergistic inhibitory effect on V. cholerae non-O1 non-0139 in vitro.",
keywords = "Combined antibiotics, Microbial sensitivity tests, Vibrio cholerae non-O1, Vibrio infections",
author = "Su, {Bo An} and Tang, {Hung Jen} and Wang, {Yin Yi} and Liu, {Yung Ching} and Ko, {Wen Chien} and Liu, {Cheng Yi} and Chuang, {Yin Ching}",
year = "2005",
month = "12",
language = "English",
volume = "38",
pages = "425--429",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - In vitro antimicrobial effect of cefazolin and cefotaxime combined with minocycline against Vibrio cholerae non-O1 non-O139

AU - Su, Bo An

AU - Tang, Hung Jen

AU - Wang, Yin Yi

AU - Liu, Yung Ching

AU - Ko, Wen Chien

AU - Liu, Cheng Yi

AU - Chuang, Yin Ching

PY - 2005/12

Y1 - 2005/12

N2 - The most common clinical manifestation of Vibrio cholerae non-O1 non-O139 is gastroenteritis. This vibrion may also cause bacteremia, soft tissue infection, and other extraintestinal invasive disease, especially in immunocompromised patients. This study evaluated the current status of antimicrobial resistance in clinical isolates of V. cholerae non-O1 non-O139 in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Minimal inhibitory concentrations (MICs) of 9 antimicrobial agents were determined by the agar dilution method. All of the isolates were susceptible to minocycline (MIC at which 90% of the isolates were inhibited [MIC90], 0.12 μg/mL), cefotaxime (MIC90, 0.06 μg/mL), lomefloxacin (MIC90, 0.12 μg/mL), levofloxacin (MIC90, 0.03 μg/mL), ciprofloxacin (MIC90, 0.03 μg/mL), moxifloxacin (MIC90, 0.06 μg/mL), sparfloxacin (MIC90, 0.06 μg/mL), gatifloxacin (MIC90, 0.03 μg/mL), and cefazolin (MIC90, 8 μg/mL). We conducted time-kill studies to evaluate the inhibitory activities of either cefazolin or minocycline alone or in combination against V. cholerae non-O1 non-O139 (Vc2). We also evaluated the inhibitory activity of cefazolin or cefotaxime combined with minocycline. The individual MICs of cefazolin, cefotaxime, and minocycline were 4 μg/mL, 0.0075 μg/mL, and 0.12 μg/mL, respectively, when approximately 5 × 105 colony-forming units/mL of V. cholerae non-O1 non-O139 was incubated. Bacterial growth was inhibited initially but resumed later when cefazolin, cefotaxime, or minocycline was used alone. When cefazoline or cefotaxime was combined with minocycline, V. cholerae non-O1 non-O139 was inhibited over 48 h and no regrowth was noted. We conclude that the combination of cefazolin or cefotaxime with minocycline has a synergistic inhibitory effect on V. cholerae non-O1 non-0139 in vitro.

AB - The most common clinical manifestation of Vibrio cholerae non-O1 non-O139 is gastroenteritis. This vibrion may also cause bacteremia, soft tissue infection, and other extraintestinal invasive disease, especially in immunocompromised patients. This study evaluated the current status of antimicrobial resistance in clinical isolates of V. cholerae non-O1 non-O139 in Taiwan as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Minimal inhibitory concentrations (MICs) of 9 antimicrobial agents were determined by the agar dilution method. All of the isolates were susceptible to minocycline (MIC at which 90% of the isolates were inhibited [MIC90], 0.12 μg/mL), cefotaxime (MIC90, 0.06 μg/mL), lomefloxacin (MIC90, 0.12 μg/mL), levofloxacin (MIC90, 0.03 μg/mL), ciprofloxacin (MIC90, 0.03 μg/mL), moxifloxacin (MIC90, 0.06 μg/mL), sparfloxacin (MIC90, 0.06 μg/mL), gatifloxacin (MIC90, 0.03 μg/mL), and cefazolin (MIC90, 8 μg/mL). We conducted time-kill studies to evaluate the inhibitory activities of either cefazolin or minocycline alone or in combination against V. cholerae non-O1 non-O139 (Vc2). We also evaluated the inhibitory activity of cefazolin or cefotaxime combined with minocycline. The individual MICs of cefazolin, cefotaxime, and minocycline were 4 μg/mL, 0.0075 μg/mL, and 0.12 μg/mL, respectively, when approximately 5 × 105 colony-forming units/mL of V. cholerae non-O1 non-O139 was incubated. Bacterial growth was inhibited initially but resumed later when cefazolin, cefotaxime, or minocycline was used alone. When cefazoline or cefotaxime was combined with minocycline, V. cholerae non-O1 non-O139 was inhibited over 48 h and no regrowth was noted. We conclude that the combination of cefazolin or cefotaxime with minocycline has a synergistic inhibitory effect on V. cholerae non-O1 non-0139 in vitro.

KW - Combined antibiotics

KW - Microbial sensitivity tests

KW - Vibrio cholerae non-O1

KW - Vibrio infections

UR - http://www.scopus.com/inward/record.url?scp=33344459774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344459774&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 425

EP - 429

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 6

ER -